SRR1414684
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1084484 | GTEX | — | 0.874 |
| 2 | SRR1410448 | GTEX | — | 0.871 |
| 3 | SRR615934 | GTEX | — | 0.871 |
| 4 | SRR1498482 | GTEX | — | 0.870 |
| 5 | MDT-AP-1152 | Med | Medulloblastoma | 0.867 |
| 6 | SRR1440876 | GTEX | — | 0.865 |
| 7 | SRR1394297 | GTEX | — | 0.862 |
| 8 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.861 |
| 9 | SRR665670 | GTEX | — | 0.861 |
| 10 | SRR1086561 | GTEX | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.469 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.435 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.429 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.365 | Idelalisib | — uncovered |
| COAGULATION | 0.329 | Binimetinib | — uncovered |
| COMPLEMENT | 0.294 | Inavolisib | — uncovered |
| MYOGENESIS | 0.284 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.259 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.259 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.255 | Inavolisib | — uncovered |
| APOPTOSIS | 0.221 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.209 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.171 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.162 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.161 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.156 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.131 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.117 | Inavolisib | — uncovered |